{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:05:27Z","timestamp":1782835527091,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LMS25H080003"],"award-info":[{"award-number":["LMS25H080003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108232","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:08:10Z","timestamp":1775808490000},"page":"108232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study"],"prefix":"10.1016","volume":"166","author":[{"given":"Fei","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-4824","authenticated-orcid":false,"given":"Jinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108232_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.trecan.2025.01.006","article-title":"Revumenib: a new era in acute leukemia treatment","volume":"11","author":"Mart\u00ednez-Gamboa","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.leukres.2026.108232_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108232_bib3","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/cells14231841","article-title":"Synergy in immunostimulatory and pro-differentiation effects of vitamin d analog and fludarabine in acute myeloid leukemias","volume":"14","author":"Haldar","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.leukres.2026.108232_bib4","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1634\/theoncologist.2017-0147","article-title":"In-hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample","volume":"22","author":"Durani","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2026.108232_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.htct.2023.02.005","article-title":"Tumor lysis syndrome in hematological inpatients: Experience from a university hospital in Brazil","volume":"46","author":"Calvache","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.leukres.2026.108232_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-0881-4","article-title":"Revolution of chronic lymphocytic leukemia therapy: the chemo-free treatment paradigm","volume":"22","author":"Scheffold","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.leukres.2026.108232_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.leukres.2026.108232_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000534453","article-title":"Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia","volume":"147","author":"Rios-Olais","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2026.108232_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: New therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108232_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108232_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.16235","article-title":"Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia","volume":"188","author":"Esparza","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108232_bib12","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1182\/bloodadvances.2024013927","article-title":"Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax","volume":"8","author":"Valtis","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2026.108232_bib13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1177\/10781552221118635","article-title":"Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia","volume":"29","author":"Abernathy","year":"2023","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.leukres.2026.108232_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17474086.2018.1456332","article-title":"Potential of BCL2 as a target for chronic lymphocytic leukemia treatment","volume":"11","author":"Moia","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2026.108232_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12325-011-0041-1","article-title":"Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel","volume":"28","author":"Pession","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.leukres.2026.108232_bib16","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108232_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106844","article-title":"Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia","volume":"117","author":"Arora","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2026.108232_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s12185-024-03752-w","article-title":"Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era","volume":"119","author":"Toda","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108232_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107587","article-title":"Development and validation of a predictive model for tumor lysis syndrome in childhood acute lymphoblastic leukemia","volume":"146","author":"Xiao","year":"2024","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2026.108232_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40291-015-0170-3","article-title":"A novel tandem duplication assay to detect minimal residual disease in FLT3\/ITD AML","volume":"19","author":"Lin","year":"2015","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.leukres.2026.108232_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: A systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108232_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/curroncol32040213","article-title":"Incidence of tumour lysis syndrome in patients with acute myeloid leukemia during initiation of therapy with azacitidine and venetoclax: A retrospective chart review from a Canadian single-centre perspective","volume":"32","author":"Saiyin","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.leukres.2026.108232_bib23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2026.108232_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13613-022-00990-1","article-title":"Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy","volume":"12","author":"Abdel-Nabey","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.leukres.2026.108232_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119497","article-title":"Uric acid and the prediction models of tumor lysis syndrome in AML","volume":"10","author":"Ejaz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2026.108232_bib26","first-page":"899","article-title":"Tumor lysis syndrome in pediatric acute lymphoblastic leukemia at tertiary care center","volume":"35","author":"Naeem","year":"2019","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.leukres.2026.108232_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.leukres.2026.108232_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102603","article-title":"Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel","volume":"120","author":"Perissinotti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.leukres.2026.108232_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2026.108232_bib30","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ejh.14371","article-title":"Tumor lysis syndrome in acute myeloid leukemia patients treated with a venetoclax based regimen","volume":"114","author":"Rowe","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108232_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12415","article-title":"Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R \u00e9animation Respiratoire et O nco-H \u00e9matologique","volume":"162","author":"Darmon","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108232_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.12542","article-title":"Rasburicase in the prevention of laboratory and clinical tumour lysis syndrome in children with advanced mature B-NHL: A Children\u2019s Oncology Group report","volume":"163","author":"Galardy","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:39:15Z","timestamp":1781051955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S0145212626000767"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108232","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108232"}}